This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber of OHSU on his experiences as a trauma surgeon, both stateside and on the battlefield.

Generic Price Competition: https://doi.org/10.1377/hlthaff.2017.1684

Back us on Patreon! www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon will be sent accompanying slides.

Back us on Patreon! www.patreon.com/plenarysession

In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship.

ECOG-ACRIN 2511: http://doi.org/10.1200/JCO.18.00264

KEYNOTE-024 update: http://doi.org/10.1200/JCO.18.00149

Back us on Patreon! www.patreon.com/plenarysession

In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cancer research.

Profiling preexisting antibodies: doi.org/10.1001/jamaoncol.2018.5860

Back us on Patreon! www.patreon.com/plenarysession

Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible.

Back us on Patreon! www.patreon.com/plenarysession

This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado.

NY Times: https://www.nytimes.com/2018/12/31/upshot/congratulations-on-the-promotion-but-did-science-get-a-demotion.html

Back us on Patreon! patreon.com/plenarysession

We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act.

Keto diet + PI3 kinase: https://www.nytimes.com/2018/12/05/magazine/its-time-to-study-whether-eating-particular-diets-can-help-heal-us.html

COMET-1: http://doi.org/10.1200/jco.2015.65.5597

COMET-2: https://doi.org/10.1016/j.eururo.2018.11.033

Back us on Patreon! https://www.patreon.com/plenarysession

This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides.

Back us on Patreon! www.patreon.com/plenarysession

We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine."

Parachutes: https://www.bmj.com/content/363/bmj.k5094

Back us on Patreon! https://www.patreon.com/plenarysession

In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.